Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00047385 · ClinicalTrials.gov registry record · Phase 3
National Lung Screening Trial (NLST) Screening
A Phase 3 study of Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 53,454
- Enrollment target
- 20
- Study locations
NCT00047385 is a Phase 3 study of Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 53,454 participants, above the 805-participant average among 409 other Lung Cancer trials with a reported enrollment target (6540% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT00047385, a Phase 3 study of Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 53,454 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Effective screening tests should help doctors detect lung cancer early and plan curative treatment. It is not yet known whether low-dose helical computed tomography (LDCT) screening is more effective than chest radiography (CXR) screening in reducing death from lung cancer. PURPOSE: Randomized clinical trial to compare the effectiveness of LDCT scan with that of CXR in screening individuals who are at high risk for developing lung cancer.
Conditions Studied
Interventions
- DEVICE low-dose helical computed tomography
- DEVICE chest radiography
Study Locations (20)
California
- Univeristy of California, San Diego - La Jolla
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
Florida
- Mayo Clinic - Jacksonville
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Massachusetts
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Henry Ford Health System - Detroit
Minnesota
- University of Minnesota School of Public Health - Minneapolis
- Mayo Clinic Cancer Center - Rochester
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado Denver - Denver
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53,454 participants |
| Start Date | 2002-08 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00047385
The ClinicalTrials.gov registry entry for NCT00047385 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 53,454 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 805-participant average among 409 other Lung Cancer trials with a reported enrollment target (6540% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which low-dose helical computed tomography is the first listed.
NCT00047385 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00047385 about?
NCT00047385 is a clinical study titled "National Lung Screening Trial (NLST) Screening". RATIONALE: Effective screening tests should help doctors detect lung cancer early and plan curative treatment. It is not yet known whether low-dose helical computed tomography (LDCT) screening is more effective than chest radiography (CXR) screening in reducing death from lung cancer. PURPOSE: Rand...
What is the current status of trial NCT00047385?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 53,454 participants. The study started on 2002-08. Estimated completion is 2010-10.
What conditions does trial NCT00047385 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00047385?
The interventions under investigation include: low-dose helical computed tomography (DEVICE), chest radiography (DEVICE).
Who is sponsoring clinical trial NCT00047385?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00047385 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
ACTIVE NOT RECRUITING · Phase 3
-
Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
COMPLETED · Phase 3
-
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.